Valuation: Glenmark Pharmaceuticals Limited

Market Cap 619B 6.42B 5.64B 5.25B 4.81B 9.05B 9.19B 62.3B 24.34B 304B 24.11B 23.59B 1,051B P/E 2026
44.2x
P/E 2027 * 26.3x
Enterprise Value 579B 6.02B 5.28B 4.91B 4.51B 8.47B 8.6B 58.34B 22.79B 285B 22.58B 22.1B 985B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.49x
Free-Float
51.03%
Yield 2026
0.12%
Yield 2027 * 0.24%
1 day-0.59%
1 week-1.95%
Current month-0.56%
1 month+1.75%
3 months-4.67%
6 months+11.40%
Current year+7.70%
1 week 2,166
Extreme 2166
2,270
1 month 2,142.8
Extreme 2142.8
2,326.1
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 722.1
Extreme 722.1
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 11/05/2011
Director/Board Member 85 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%-1.95%+2.18%+179.57% 6.42B
-0.66%+0.44%+14.25%+77.26% 48.36B
+2.20%+1.41%+57.98%+112.68% 35.8B
+1.26%-0.57%-7.95%+33.74% 11.83B
-0.46%-3.06%+13.55%+78.32% 11.48B
-0.37%-0.37%+37.53%+140.99% 9.01B
+1.52%+0.39%+49.34%-7.78% 6.99B
-0.17%-2.92%+11.72%+32.23% 6.7B
-7.92%-13.61%-33.87%-3.07% 5.3B
-2.05%-1.46%+21.02%+122.89% 4.37B
Average -0.72%-2.05%+16.57%+76.68% 14.63B
Weighted average by Cap. +0.05%-0.48%+24.03%+83.24%

Financials

2026 2027 *
Net sales 153B 1.59B 1.4B 1.3B 1.19B 2.24B 2.27B 15.42B 6.02B 75.28B 5.97B 5.84B 260B 167B 1.73B 1.52B 1.41B 1.3B 2.44B 2.48B 16.79B 6.56B 81.96B 6.5B 6.36B 283B
Net income 20.53B 213M 187M 174M 160M 300M 305M 2.07B 808M 10.09B 800M 783M 34.9B 23.28B 242M 212M 197M 181M 340M 346M 2.34B 916M 11.45B 908M 888M 39.58B
Net Debt -39.29B -408M -358M -333M -306M -575M -583M -3.96B -1.55B -19.32B -1.53B -1.5B -66.79B -37.12B -385M -339M -315M -289M -543M -551M -3.74B -1.46B -18.25B -1.45B -1.42B -63.1B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
24/07/26 ₹2,192.00 -0.59% 429,562
23/07/26 ₹2,205.10 +0.24% 567,718
22/07/26 ₹2,199.90 -1.88% 942,175
21/07/26 ₹2,242.10 +0.12% 274,753
20/07/26 ₹2,239.50 +0.18% 914,679
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,192.00INR
Average target price
2,497.27INR
Spread / Average Target
+13.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock